Article Text

PDF
Clinical science
Stereotactic radiotherapy for treatment of juxtapapillary choroidal melanoma: 3-year follow-up
  1. H Krema1,
  2. S Somani1,
  3. A Sahgal2,
  4. W Xu3,
  5. M Heydarian4,
  6. D Payne2,
  7. H McGowan1,
  8. H Michaels4,
  9. E R Simpson1,
  10. N Laperriere2
  1. 1
    Department of Ocular Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
  2. 2
    Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
  3. 3
    Department of Biostatistics, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
  4. 4
    Department of Radiation Medicine, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
  1. Correspondence to Dr H Krema, Ocular Oncology Service, Princess Margaret Hospital, 610 University Avenue, Toronto, ON, M5G 2M9, Canada; htmkrm19{at}yahoo.com

Abstract

Aims: To report the treatment outcomes and complication rates of stereotactic radiotherapy in the management of patients with juxtapapillary choroidal melanoma.

Methods: A retrospective review of 64 consecutive patients with juxtapapillary choroidal melanoma, located within 2 mm of the optic disc, treated with stereotactic radiotherapy at Princess Margaret Hospital between October 1998 and January 2006.

Results: The median age was 63 years. The median tumour height was 4.2 mm, and median largest basal diameter was 9.8 mm. The prescribed radiation dose was 70 Gy in five fractions over 10 days, and the median follow-up was 37 months. Post-treatment, the actuarial rates of local tumour control, metastases and survival at 37 months were 94%, 15% and 90%, respectively. Actuarial rates of radiation-induced complications at 37 months were neovascular glaucoma 42%, cataract 53%, retinopathy 81% and optic neuropathy 64%. Secondary enucleation was necessary for 10 patients (16%), in four patients for tumour recurrence and in six for painful neovascular glaucoma.

Conclusions: Stereotactic radiotherapy offers a non-invasive alternative to enucleation and brachytherapy in the management of juxtapapillary choroidal melanoma with a high tumour control rate, however, at the expense of a significant rate of long-term ocular complications.

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

  • Provenance and Peer review Not commissioned; externally peer reviewed.

  • Ethics approval Ethics approval was provided by Research Ethics Board of Princess Margaret Hospital/University Health Network.

  • Patient consent Obtained.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.